MarketCapExport financials
Albireo Pharma (ALBO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Albireo Pharma Cash Flow 2021-2004 | ALBO
Brief overview of Albireo Pharma's cash generation
The comparison covers five available annual reports between 2017 and 2021.
Cash from operations is below zero at -$107.6 million, increasing dependence on cash reserves or outside financing.
Only 0 of five observations were above zero. The business relies heavily on individual strong periods.
Conclusion
Albireo Pharma's cash profile looks stretched: weak operating cash flow limits investment, payouts and debt-servicing capacity.
Annual Cash Flow Albireo Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-108 M | -101 M | -52.9 M | -26.8 M | -27.6 M | - | -18.2 M | -18.7 M | -18.6 M | -16.7 M | -18.3 M | -34.4 M | -35.3 M | - | - | - | - | - |
Depreciation & Amortization |
274 K | 192 K | 127 K | 45 K | 35 K | 14 K | 15 K | 603 K | 641 K | 725 K | 938 K | 991 K | 877 K | - | - | - | - | - |
Accounts Payables |
6.52 M | 5.28 M | 4.78 M | 4.35 M | 1.35 M | 150 K | 421 K | 172 K | 246 K | 285 K | 222 K | 1.99 M | - | - | - | - | - | - |
Accounts Receivables |
3.27 M | - | - | - | - | 26 K | 1.27 M | - | - | 9 K | 1 K | 11 K | - | - | - | - | - | - |
Total Inventories |
194 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Cash Flow Albireo Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | -101 M | -71.8 M | -35.4 M | - | -93.7 M | -66.2 M | -34.7 M | - | -72.8 M | -46.9 M | -23.8 M | - | -40.5 M | -26.5 M | -13.5 M | - | -16.8 M | -6.52 M | 1.1 M | - | -19.6 M | -14.4 M | - | - | -10.2 M | -7.65 M | -3.89 M | -3.89 M | -14.6 M | -8.99 M | -5.44 M | -5.44 M | -15.3 M | -11.1 M | -4.54 M | -4.54 M | -15 M | -11.1 M | -4.69 M | -4.69 M | -11.3 M | -7.37 M | -3.67 M | -3.67 M | -14.9 M | -11.4 M | -3.67 M |
Depreciation & Amortization |
- | 322 K | 198 K | 114 K | - | 167 K | 75 K | 37 K | - | 119 K | 77 K | 39 K | - | 89 K | 50 K | 11 K | - | 33 K | 22 K | 53 K | - | 23 K | 13 K | 5 K | - | 81 K | 80 K | 30 K | 30 K | 211 K | 164 K | 102 K | 102 K | 462 K | 310 K | 156 K | 156 K | 484 K | 326 K | 167 K | 167 K | 555 K | 382 K | 194 K | 194 K | 732 K | 502 K | 194 K |
Accounts Payables |
- | 6.95 M | 5.39 M | 6.37 M | 6.52 M | 7.22 M | 5.7 M | 6.58 M | 5.28 M | 3.6 M | 4.73 M | 6.79 M | 4.78 M | 3.18 M | 3.84 M | 2.99 M | 4.35 M | 3.48 M | 3.02 M | 2.25 M | 1.35 M | 1.58 M | 1.33 M | 1.31 M | 972 K | 467 K | 115 K | 335 K | 335 K | 189 K | 346 K | 435 K | 435 K | 374 K | 641 K | 1.79 M | 1.79 M | 240 K | 312 K | 1.13 M | 1.13 M | 180 K | 114 K | 151 K | 151 K | 102 K | 222 K | 222 K |
Accounts Receivables |
- | 2.03 M | 1.85 M | 1.28 M | 3.27 M | 1.31 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11 K | 26 K | 1 K | 26 K | - | 26 K | 26 K | 1.27 M | - | - | - | - | - | - | - | - | 9 K | 9 K | 9 K | - | 1 K | 1 K | 1 K | - | 1 K | 1 K | 1 K |
Total Inventories |
- | 3.15 M | 2.1 M | 1.82 M | 194 K | 196 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Albireo Pharma, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Biotechnology sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Lexicon Pharmaceuticals
LXRX
|
$ 1.78 | 10.25 % | $ 646 M |  USA |
 |
Moleculin Biotech
MBRX
|
$ 8.87 | 1.6 % | $ 10.5 M | USA |
 |
Nurix Therapeutics
NRIX
|
$ 15.3 | 3.1 % | $ 1.33 B | USA |
 |
Nkarta
NKTX
|
$ 1.75 | 11.15 % | $ 129 M | USA |
 |
MacroGenics
MGNX
|
$ 2.35 | 5.86 % | $ 148 M | USA |
 |
Protagonist Therapeutics
PTGX
|
$ 131.96 | -2.54 % | $ 8.39 B | USA |
 |
Nuvation Bio
NUVB
|
$ 4.15 | -0.72 % | $ 1.42 B | USA |
 |
Novo Nordisk A/S
NVO
|
$ 40.36 | 0.21 % | $ 179 B |  Danmark |
 |
Marker Therapeutics
MRKR
|
$ 0.91 | 0.95 % | $ 13.9 M | USA |
 |
NextCure
NXTC
|
$ 5.55 | 8.61 % | $ 15.8 M | USA |
 |
PMV Pharmaceuticals
PMVP
|
$ 1.25 | -1.57 % | $ 65.7 M | USA |
 |
Olema Pharmaceuticals
OLMA
|
$ 7.32 | 8.21 % | $ 637 M | USA |
 |
Kymera Therapeutics
KYMR
|
$ 132.5 | 3.42 % | $ 11.2 B | USA |
 |
Oragenics
OGEN
|
$ 0.35 | 0.29 % | $ 755 K | USA |
 |
Ovid Therapeutics
OVID
|
$ 2.86 | 10.66 % | $ 372 M | USA |
 |
Passage Bio
PASG
|
$ 3.9 | 12.72 % | $ 12.5 M | USA |
 |
Vaxcyte
PCVX
|
$ 63.86 | 3.13 % | $ 8.69 B | USA |
 |
Relay Therapeutics
RLAY
|
$ 18.59 | 9.32 % | $ 3.19 B | USA |
 |
Precigen
PGEN
|
$ 4.47 | 5.81 % | $ 1.4 B | USA |
 |
Avidity Biosciences
RNA
|
$ 8.36 | 0.48 % | $ 1.15 B | USA |
 |
Phio Pharmaceuticals Corp.
PHIO
|
$ 0.8 | -1.38 % | $ 4.79 M | USA |
 |
Praxis Precision Medicines
PRAX
|
$ 277.94 | 5.85 % | $ 6.25 B | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
$ 3.59 | 0.98 % | $ 276 M | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
$ 1.36 | 1.88 % | $ 143 M |  Niderland |
 |
Ocular Therapeutix
OCUL
|
$ 6.61 | 2.8 % | $ 1.24 B | USA |
 |
PolyPid Ltd.
PYPD
|
$ 6.08 | 7.23 % | $ 99.4 M |  Israel |
 |
Outlook Therapeutics
OTLK
|
$ 0.44 | -0.93 % | $ 15.3 M | USA |
 |
uniQure N.V.
QURE
|
$ 21.68 | 3.19 % | $ 1.25 B | Niderland |
 |
Ultragenyx Pharmaceutical
RARE
|
$ 15.48 | -0.58 % | $ 1.53 B | USA |
 |
Rafael Holdings
RFL
|
$ 1.02 | -4.67 % | $ 52.4 M | USA |
 |
REGENXBIO
RGNX
|
$ 7.62 | 3.25 % | $ 393 M | USA |
 |
Rigel Pharmaceuticals
RIGL
|
$ 39.52 | -13.54 % | $ 711 M | USA |
 |
Celsion Corporation
CLSN
|
- | -6.63 % | $ 13.9 M | USA |
 |
Генетико
GECO
|
- | - | - |  Russia |
 |
I-Mab
IMAB
|
- | - | $ 866 M |  China |
 |
Tenax Therapeutics
TENX
|
$ 1.68 | 3.07 % | $ 65.9 M | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | France |
 |
Scholar Rock Holding Corporation
SRRK
|
$ 46.77 | 2.78 % | $ 5.36 B | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M |  Germany |
 |
Spero Therapeutics
SPRO
|
$ 1.03 | 1.47 % | $ 57.7 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
- | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
- | - | $ 4.9 B |  Britain |
|
Rezolute
RZLT
|
$ 3.85 | 5.77 % | $ 400 M | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Britain |
 |
Tiziana Life Sciences PLC
TLSA
|
$ 0.69 | 11.43 % | $ 73.6 M | Britain |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Germany |
 |
Affimed N.V.
AFMD
|
- | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
- | -1.58 % | $ 28.1 M | China |